<DOC>
	<DOC>NCT00466284</DOC>
	<brief_summary>A open label non- randomized Phase II trial. It is anticipated that approximately 46 patients will be treated. STUDY OBJECTIVES Primary: Objective response rate Secondary: Progression free survival, Overall survival and Safety of Tarceva</brief_summary>
	<brief_title>Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Study Design: Phase II trial, open label, non-randomized and multicenter. Expected total enrollment: 46 Study start: January, 2006 Study completation: January, 2008</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age 18 years. Patients must have histologically confirmed diagnosis of nonsmall cell lung cancer, which is not surgically resectable (stage IA IIIB). Measurable disease. Written informed consent must be obtained prior to the inclusion into the trial. Karnofsky performance status of 80%. Patients must have been treated with no prior chemotherapy or radioterapy. Patients must have adequate bone marrow, liver and renal function. Bone Marrow: WBC &gt; 3000 x 103/mm3, Platelets &gt; 100 x 103/mm3, Hgb &gt; 10.0 gm/dl, ANC &gt;1500 x 103/mm3, Hepatic:Bilirubin &lt; 2 mg/dl (34 µmol/l); AST, ALT, and Alkaline Phosphatase &lt; 5 x normal, Renal:Creatinine &lt; 1.5 mg/dl (132 µmol/l). Female patients who are pregnant or lactating. Patients who have used other investigational agents within 21 days prior to study entry. Patients who have received prior treatment with erlotinib or other antiEGFR agent. Significant comorbidity.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>